Takeda, M., Shimokawa, M., Nakamura, A., Nosaki, K., Watanabe, Y., Kato, T., Hayakawa, D., Tanaka, H., Takahashi, T., Oki, M., Tachihara, M., Fujimoto, D., Hayashi, H., Yamaguchi, K., Yamamoto, S., Iwama, E., Azuma, K., Hasegawa, K., Yamamoto, N., & Nakagawa, K. (2023). a phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy. Lung cancer, 177, 44–50. http://access.bl.uk/ark:/81055/vdc_100177580951.0x00005b